Bristol’s Baraclude Label Adds Boxed Warning On Use In HIV/HBV Co-Infection
This article was originally published in The Pink Sheet Daily
Executive Summary
Updated labeling recommends HIV antibody screening prior to use and reinforces that entecavir is not recommended for HIV/HBV co-infected patients not on highly active antiretroviral therapy.